[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356408-105":59,"doc-detail-356408-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","biomarker-recall-and-understanding-among-people-living-with-metastatic-breast-cancer-results-from-an-international-patient-survey","Biomarker recall and understanding among people living with metastatic breast cancer - results from an international patient survey","","Scientific advancements have increased biomarker testing for metastatic breast cancer treatment decisions, yet added complexity can affect how well patients understand biomarker information and their diagnosis. An online, multi-language 15-question survey assessed patient recall, understanding, and barriers to learning about breast cancer subtype among people with self-reported metastatic breast cancer. Results across 36 countries show limited recall of biomarker terminology and subtype meaning, with major geographic variation and inadequate information from HCPs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/biomarker-recall-and-understanding-among-people-living-with-metastatic-breast-cancer-results-from-an-international-patient-survey/356408/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/biomarker-recall-and-understanding-among-people-living-with-metastatic-breast-cancer-results-from-an-international-patient-survey/356408.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study designed to evaluate?","Question",{"text":112,"@type":113},"The study assessed patient recall and understanding of biomarker information, and identified barriers to understanding diagnosis for metastatic breast cancer. It also examined how much information patients felt healthcare professionals provided about breast cancer subtype.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was data collected in the study?",{"text":117,"@type":113},"An online, multi-language 15-question multiple choice survey was distributed to people with self-reported metastatic breast cancer. Responses included demographics, disease history, information-seeking behaviour, and barriers to learning their breast cancer subtype.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings on biomarker and subtype understanding?",{"text":121,"@type":113},"Recall of the term “biomarker” was low (8%), while 33% of patients did not understand their breast cancer subtype and its meaning. Only 44% of patients felt healthcare professionals provided sufficient information about their subtype, and recall varied significantly by geography.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356408,1790867518,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","The Breast 86 (2026) 104737  \nContents lists available at ScienceDirect  \nThe Breast  \njournal [homepage:](homepage: www.journals.elsevier.com/the-breast)[ www.journals.elsevier.com/the-breast](homepage: www.journals.elsevier.com/the-breast)  \n| Biomarker recall and understanding among people living with metastatic breast cancer – results from an international patient survey |  |  | |\n| --- | --- | --- | --- |\n| Eva Schumacher-Wulf a, Lesley Fallowfield b, Runcie C.W. Chidebec,d, Vicki Durstone,\u003Cbr>Alexandru Eniuf,g, Ranjit Kaur h, Renate Haidinger i, Nisha Pillayj, Daniel Egbase j , Yi Han j,*\u003Cbr>FatimammaCa! rdosagazineo, k,Cologne, Germany\u003Cbr>b Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Falmer, East Sussex, UK c Project PINK BLUE-Health & Psychological Trust Centre, Abuja, Nigeria\u003Cbr>d Department of Sociology and Gerontology, Miami University, Oxford, OH, USA\u003Cbr>e Breast Cancer Network Australia, Melbourne, VIC, Australia f Genolier Cancer Center, Genolier, Switzerland\u003Cbr>g European School of Oncology, Bellinzona, CH, Switzerland h National Cancer Society Malaysia, Kuala Lumpur, Malaysia i Brustkrebs Deutschland e. V., Munich, Germany\u003Cbr>j VML Health, London, UK\u003Cbr>k Advanced Breast Cancer (ABC) Global Alliance, Lisbon, Portugal |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>Metastatic breast cancer Biomarker\u003Cbr>Subtype\u003Cbr>Patient survey\u003Cbr>Shared decision-making |  | Background: Scientific advancements have increased the use of biomarker testing for metastatic breast cancer (mBC) treatment decisions, adding complexity which may impact patient understanding. This study assesses patient recall and understanding of biomarker information and barriers to understanding diagnosis.\u003Cbr>Materials and methods: An online, multi-language, 15-question multiple choice survey was distributed to people with a self-reported diagnosis of mBC through the Advanced Breast Cancer (ABC) Global Alliance. Data collected included patient demographics, disease history, information seeking behaviour, and barriers to learning about their breast cancer subtype.\u003Cbr>Results: Across 36 countries, 1064 respondents completed the survey. 81% recognised that their breast cancer subtype influences treatment decisions, though there was wide variation in patient recall of terminology used by their healthcare professionals (HCPs).\u003Cbr>Recall of the term ‘biomarker’ was low (8%). Geographical differences existed in patient recall of specific biomarkers used to describe mBC diagnosis; ‘hormone receptor-positive (HR+)’ recall was significantly higher for patients from North America (73%), compared with other regions (14%–56%). One-third (33%) of patients did not understand their breast cancer subtype and what it means.\u003Cbr>Only 44% of patients felt HCPs had given them sufficient information about their breast cancer subtype. A subset of patients (7%) reported not wanting to learn more, with the highest proportion from Latin America (17%). Conclusions: Findings demonstrate limited patient recall and understanding of breast cancer biomarkers and subtype, with significant variation based on geography. Results may be used to improve two-way communication and patient understanding regarding biomarker status, to facilitate shared decision-making. |  |\n\n1. Introduction  \nThe global burden of breast cancer is rising, with over 2.3 million new cases in 2022, making it the second most common cancer [1].  \nIncidence is projected to increase by more than 45% by 2045 and approximately 30–40% of these patients will experience metastatic disease [1,2]. As part of a broader shift in cancer care, the field of oncology has been focusing on personalised medicine, where treatments  \n* Corresponding author.  \nE-mail address: [fcardoso@abcglobalalliance.org](fcardoso@abcglobalalliance.org) (F. Cardoso).  \n[https://doi.org/10.1016/j.breast.2026.104737](https://doi.org/10.1016/j.brea","cbCaiiGxbQ9T3hui","https://ap.wps.com/l/cbCaiiGxbQ9T3hui","pdf",3360503,"English","# Introduction\n# Materials and methods\n# Results\n# Conclusions","[{\"question\":\"What was the study designed to evaluate?\",\"answer\":\"The study assessed patient recall and understanding of biomarker information, and identified barriers to understanding diagnosis for metastatic breast cancer. It also examined how much information patients felt healthcare professionals provided about breast cancer subtype.\"},{\"question\":\"How was data collected in the study?\",\"answer\":\"An online, multi-language 15-question multiple choice survey was distributed to people with self-reported metastatic breast cancer. Responses included demographics, disease history, information-seeking behaviour, and barriers to learning their breast cancer subtype.\"},{\"question\":\"What were the key findings on biomarker and subtype understanding?\",\"answer\":\"Recall of the term “biomarker” was low (8%), while 33% of patients did not understand their breast cancer subtype and its meaning. Only 44% of patients felt healthcare professionals provided sufficient information about their subtype, and recall varied significantly by geography.\"}]","Biomarker recall and understanding among people living with metastatic breast cancer - results from an international patient survey | PDF",1790125243,23]